[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100557673":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":12,"centralContacts":16,"locations":21,"responsibleParty":34,"collaborators":7,"id":36,"slug":37,"hasResults":38,"nctId":39,"briefTitle":40,"officialTitle":41,"acronym":42,"eligibilityCriteria":43,"healthyVolunteers":38,"sex":44,"minAge":45,"maxAge":7,"enrollmentInfo":46,"targetDuration":7,"studyType":49,"phases":7,"briefSummary":50,"conditions":51,"keywords":7,"overallStatus":54,"whyStopped":7,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":64},{"fullName":5,"class":6},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","OTHER",null,[9],{"type":6,"name":10,"description":11,"armGroupLabels":7,"otherNames":7},"Magnetic resonance imaging as fpr clinical practice","An abbreviated MR protocol of the abdomen will be used inh association with CT scan; it does not need contrast injection and does not add any risk for patients.",[13],{"name":14,"affiliation":5,"role":15},"Giacomo Avesani","PRINCIPAL_INVESTIGATOR",[17],{"name":14,"role":18,"phone":19,"phoneExt":7,"email":20},"CONTACT","+390630156054","giacomo.avesani@policlinicogemelli.it",[22],{"facility":23,"status":7,"city":24,"state":7,"zip":25,"country":26,"countryCode":27,"cosmosGeoPoint":28,"geoPoint":33,"contacts":7},"Fondazione Policlinico Universitaro \"A. Gemelli\" IRCCS","Roma","00168","Italy","IT",{"type":29,"coordinates":30},"Point",[31,32],11.10642,44.99364,{"lat":32,"lon":31},{"type":35,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100557673","a-new-fast-dwi-based-mr-protocol-for-surveillance-in-patients-with-a-high-risk-of-ovarian-cancer-recurrence-during-parp-inhibitors-maintenance-to-enhance-secondary-cytoreduction-results-100557673",false,"NCT06541171","A New Fast DWI-based MR Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results","A New Fast DWI-based Magnetic Resonance Protocol for Surveillance in Patients With a High Risk of Ovarian Cancer Recurrence During PARP-inhibitors Maintenance to Enhance Secondary Cytoreduction Results","FOFU","Inclusion Criteria:\n\n* Patients with BRCA wild-type, HRP, high-grade serous ovarian cancer\n* No residual tumour at first debulking surgery\n* More than 6 months since the last platinum-based therapy\n\nExclusion Criteria:\n\n* Patients who will not consent to participate in the study","FEMALE","18 Years",{"count":47,"type":48},220,"ESTIMATED","OBSERVATIONAL","In ovarian cancer (OC), complete surgical debulking and platinum-based chemotherapy are the standard treatment, now followed by maintenance therapy with PARP inhibitors or Bevacizumab. However, in advanced-stage ovarian cancer, recurrence is common, with a progression-free survival of about 16 months. Secondary cytoreductive surgery (SCS) at the time of recurrence prolongs the overall survival and gives the possibility to extend the use of PARP-i. SCS is possible only when recurrence has limited extension. However, in OC, there is no well-established and widely accepted scheme for surveillance during maintenance therapy; ESMO guidelines suggest physical examination for the follow-up and allow ultrasound, CT, PET-CT and MRI to confirm the recurrence and plan surgical treatment if appropriate.",[52,53],"Ovarian Cancer","Recurrent Ovarian Carcinoma","NOT_YET_RECRUITING","2024-08-02",{"date":57,"type":58},"2024-08-07","ACTUAL",{"date":60,"type":48},"2024-09-01",{"date":62,"type":48},"2027-08-31",{"name":5,"class":6},1]